https://pjmedia.com/news-and-politics/stacey-lennox/2020/05/14/new-hydroxychloroquine-trial-could-be-destined-to-fail-n392407
The politicization of hydroxychloroquine has been one of the most frustrating aspects of Trump Derangement Syndrome during this pandemic. Early studies in France and clinical outcomes from multiple treating physicians using a combination therapy that included the drug provided hope to combat the virus. However, it made President Trump hopeful, so it had to be obliterated.
Crappy studies of the drug given to the most severe patients were touted as proof the president was wrong. Then there was Fish Tank Cleaner Gate. This is the problem with political reporters covering press briefings about a pandemic. They either aren’t provided an internet connection by their employers or are too lazy to do 15 minutes of research.
Now, the NIH has finally announced it will begin a clinical trial using hydroxychloroquine and azithromycin in COVID-19 patients with mild to moderate symptoms. Every clinician who has advocated hydroxychloroquine-azithromycin has said this is the appropriate stage of the disease to use the drug combination. Dr. Vladimir Zelenko began giving it to diagnosed and presumed COVID-19 patients during a severe outbreak in New Rochelle, New York. He started the drug when patients were suffering from mild shortness of breath.
Dr. Anthony Cardillo also explained how he effectively used the drug. His method was to give the medicine with azithromycin and zinc for a specific biological reason. This mineral needs to be added to the NIH trial based on volumes of scientific research on how it works in combination with hydroxychloroquine. Cardillo explained it succinctly:
“It was actually the hydroxychloroquine opening up a channel in the cellular membranes allowing zinc to come into the cells,” he said, “And we do know high levels of zinc inside of the cell that’s infected with the virus shuts down that viral replication machinery.”
The reaction to hydroxychloroquine was very perplexing. The NIH studied drug’s older cousin chloroquine following the SARS epidemic. In 2005 the NIH noted chloroquine had both prophylactic effects for prevention and anti-viral effects in cell cultures:
Conclusion